Bionano Genomics Announces Participation at the European Association for Cancer Research (EACR) Congress 2022 Featuring OGM Applications for Cancer Research
- Bionano will exhibit its solutions relevant to cancer research: the Saphyr® system, NxClinical™ software and expert laboratory services
- A corporate satellite presentation by
Alicia Bertolotti, Bionano, Dr. Sylvia Genovese, Bambino Gesù Children’s Hospital, and Dr. Juan Díaz-Martín, Institute of Biomedicine of Sevilla(IBiS), will cover the use of OGM for clinical research applications in solid tumor analysis
- 3 poster presentations will illustrate the application of Bionano’s OGM solutions, one each in solitary fibrous tumors, Clear Cell Sarcoma (CCS), and neuroendocrine tumor research
EACR 2022 is a four-day congress dedicated to basic, preclinical, and translational cancer research. EACR sessions will take place June 20-23, 2022 in
A corporate satellite session, titled “See More, Know More: Bionano Helps You Go Deeper in the Understanding of Your Complex Samples,” will feature genomics researchers highlighting use of OGM in solid tumor analysis.
Scientific presentations and poster sessions from Bionano and collaborators include:
|Auditorium 2 + 3||See More, Know More: Bionano Helps You Go Deeper in the Understanding of Your Complex Samples||Bertolotti A., Genovese S., Díaz-Martín J.|
|Session 1||Exploring the Role of Endoglin in the Aggressiveness of Ewing Sarcoma and Clear Cell Sarcoma||Amaral A.|
|Session 1||Optical Genome Mapping: Unravelling the Genomic Landscape of Solitary Fibrous Tumor|
|Session 2||Whole-genome Optical Mapping Reveals a Complex Genetic Architecture Involving Translocations in Pheochromocytomas||Manakova J.|
More details on the conference can be found here.
“We believe the information covered in these EACR presentations demonstrates the ongoing progress of OGM becoming an essential tool in the arsenal of cancer researchers,” commented
also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.
Forward-Looking Statements of
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “can,” “believe,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the ability of OGM and NxClinical software to offer useful clinical research applications for solid tumor analysis and hematological malignancies or deliver significant advantages relative to the current standard of care. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; the inability of OGM or NxClinical software to offer useful clinical research applications for solid tumor analysis and hematological malignancies or delivery advantages relative to the current standard of care; future study results contradicting the results reported in the presentations given and posters made available at EACR 2022
+1 (858) 888-7610
+1 (858) 366-3243
Source: Bionano Genomics